Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
| ▸ | CCR2 | P41597 | 1/20 | 0.32 |
| ▸ | PIM1 | P11309 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL744557 | 0.72 | OPRM1 (0.35) | OPRM1OPRL1LRRK2 | |
| SCHEMBL27621989 | 0.70 | — | — | |
| SCHEMBL20887803 | 0.69 | OPRM1 (0.49) | OPRM1OPRL1 | |
| SCHEMBL2485114 | 0.69 | HCAR2 (0.37) | CCR2 | |
| SCHEMBL2481834 | 0.69 | SMN1; SMN2 (0.34) | — | |
| SCHEMBL743773 | 0.68 | MEN1 (0.35) | — | |
| SCHEMBL2486031 | 0.68 | HCAR3 (0.37) | — | |
| SCHEMBL2509684 | 0.68 | CCR2 (0.31) | CCR2 | |
| SCHEMBL2482849 | 0.68 | PKLR (0.35) | CCR2 | |
| SCHEMBL27920311 | 0.67 | LRRK2 (0.41) | OPRM1OPRL1LRRK2CCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023081665-A1 | COMPOUNDS AS CRR2 MODULATORS | ARIA PHARMACEUTICALS, INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| EP-2376475-B1 | 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANOL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2015-09-02 | — | — | EP | disclosed |
| EP-2376475-B1 | 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANOL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2015-09-02 | — | — | EP | disclosed |
| EP-2582692-B1 | CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2015-07-22 | — | — | EP | disclosed |
| EP-2582692-B1 | CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2015-07-22 | — | — | EP | disclosed |
| US-9062048-B2 | Cyclohexyl-azetidinyl antagonists of CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2015-06-23 | — | — | US | disclosed |
| US-9062048-B2 | Cyclohexyl-azetidinyl antagonists of CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2015-06-23 | — | — | US | disclosed |
| US-9062048-B2 | Cyclohexyl-azetidinyl antagonists of CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2015-06-23 | — | — | US | disclosed |
| EP-2580208-B1 | CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2015-05-06 | — | — | EP | disclosed |
| US-20130310365-A1 | CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICAL NV (BE) | 2013-11-21 | — | — | US | disclosed |
| WO-2010068663-A1 | 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANOL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA NV (BE) | 2010-06-17 | — | — | WO | disclosed |
| US-20100144695-A1 | 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANOL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-06-10 | — | — | US | disclosed |
| US-20100144695-A1 | 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANOL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-06-10 | — | — | US | disclosed |
| US-20100144695-A1 | 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANOL ANTAGONISTS OF CCR2 | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-06-10 | — | — | US | disclosed |
| US-7307086-B2 | 3-(4-heteroarylcyclohexylamino)cyclopentanecarboxamides as modulators of chemokine receptors | INCYTE CORPORATION (US) | 2007-12-11 | — | — | US | disclosed |
| US-7307086-B2 | 3-(4-heteroarylcyclohexylamino)cyclopentanecarboxamides as modulators of chemokine receptors | INCYTE CORPORATION (US) | 2007-12-11 | — | — | US | disclosed |
| US-7307086-B2 | 3-(4-heteroarylcyclohexylamino)cyclopentanecarboxamides as modulators of chemokine receptors | INCYTE CORPORATION (US) | 2007-12-11 | — | — | US | disclosed |
| EP-1746997-A2 | 3-(4-HETEROARYLCYCLOHEXYLAMINO) CZCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS | Incyte Corporation (US) | 2007-01-31 | — | — | EP | disclosed |
| WO-2005115392-A2 | 3-(4-HETEROARYLCYCLOHEXYLAMINO) CYCLOPENTANECARBOXAMIDES AS MODULATORS OF CHEMOKINE RECEPTORS | INCYTE CORPORATION (US) | 2005-12-08 | — | — | WO | disclosed |
| US-20050267146-A1 | 3-(4-Heteroarylcyclohexylamino)cyclopentanecarboxamides as modulators of chemokine receptors | INCYTE CORPORATION | 2005-12-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130310365-A1 | CYCLOHEXYL-AZETIDINYL ANTAGONISTS OF CCR2 | CCR2, CCR1, CCR5 | OPRM1 448/4885OPRL1 48/4885LRRK2 4085/4885 |
| US-20100144695-A1 | 4-AZETIDINYL-1-HETEROARYL-CYCLOHEXANOL ANTAGONISTS OF CCR2 | CCR2, CCR1, CCRL2 | OPRM1 344/4885OPRL1 80/4885LRRK2 3178/4885 |
| US-20050267146-A1 | 3-(4-Heteroarylcyclohexylamino)cyclopentanecarboxamides as modulators of chemokine receptors | CCR5, CXCR3, CCR2 | OPRM1 144/4885OPRL1 87/4885LRRK2 2849/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.